Chargement en cours...
LAG3 (CD223) as a Cancer Immunotherapy Target
Despite the impressive impact of CTLA4 and PD1-PDL1 targeted cancer immunotherapy, a large proportion of patients with many tumor types fail to respond. Consequently, the focus has shifted to targeting alternative inhibitory receptors (IRs) and suppressive mechanisms within the tumor microenvironmen...
Enregistré dans:
| Publié dans: | Immunol Rev |
|---|---|
| Auteurs principaux: | , , , |
| Format: | Artigo |
| Langue: | Inglês |
| Publié: |
2017
|
| Sujets: | |
| Accès en ligne: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5338468/ https://ncbi.nlm.nih.gov/pubmed/28258692 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1111/imr.12519 |
| Tags: |
Ajouter un tag
Pas de tags, Soyez le premier à ajouter un tag!
|